Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Naporafenib - Erasca

Next Previous
Drug Profile

Naporafenib - Erasca

Alternative Names: ERAS-254; LXH-254

Latest Information Update: 23 May 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Novartis
  • Developer Erasca; Novartis
  • Class Amides; Antineoplastics; Fluorocarbons; Morpholines; Pyridines; Small molecules
  • Mechanism of Action Proto oncogene protein c raf inhibitors; Proto-oncogene protein b-raf inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase III Malignant melanoma
  • Phase I Solid tumours
  • No development reported Colorectal cancer; Non-small cell lung cancer

Most Recent Events

  • 13 May 2025 Naporafenib - Erasca is available for licensing as of 13 May 2025
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Australia (PO, Tablet)
  • 28 Apr 2025 No recent reports of development identified for phase-I development in Colorectal-cancer(Combination therapy, Late-stage disease, Metastatic disease) in Belgium (PO, Tablet)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top